STAAR Surgical (STAA) Q3 2026 Earnings Call Transcript

STAAR Surgical reported Q3 net sales of $83.4 million, down 12% year over year because the prior-year quarter included $25.9 million of deferred China sales; excluding that comparison item, sales grew 21%, including 31% adjusted growth in China. GAAP net income was $5.6 million versus an adjusted prior-year net loss of $6.3 million, while adjusted EBITDA rose to $14.4 million from $8.9 million; gross margin declined to 70.9% from an adjusted 75.5% amid temporary manufacturing, freight, tariff and inventory costs. Management expects Q4 gross margin to exceed Q3 and unit costs to improve in 2027, while noting constrained lens supply in Q3 and no formal forward revenue guidance. The company ended the quarter with $206.4 million in cash and investments, no debt, and a $50 million share repurchase authorization; first-in-human trials for two presbyopia products are expected to begin enrollment in the coming months, subject to regulatory authorization.

Analysis

STAAR (STAA): positive operating inflection, but execution—not headline growth—is the trade. The key asymmetry is that China demand appears stronger than the company’s ability to supply, while reported growth is currently getting help from premium product mix. If added Swiss capacity and better yields translate into more units shipped, revenue can become less dependent on ASP/mix and fixed-cost absorption can support margin recovery. But unmet demand is not automatically deferred revenue: patients may wait, substitute, or choose another procedure. Distributor sell-through is a useful signal, not proof of implants or future sell-in.

Near term, ERP-related inventory, freight, and manufacturing costs constrain earnings conversion; management’s Q4 margin improvement is a test, not yet a demonstrated trend. Over 1–3 months, watch China unit shipments versus ASP, made-to-order backlog, and gross margin. Over 6–18 months, presbyopia trials offer portfolio optionality, but enrollment and regulatory progress are catalysts—not a basis for near-term earnings estimates. Laser-to-lens substitution could benefit ICL-capable practices, while laser-centric providers risk losing share; however, a shrinking procedure pool could limit category growth. EssilorLuxottica’s clinic expansion is a possible future channel development, not evidence of an immediate benefit or threat to STAAR.

Contrarian read: the mix-led China growth and below-target channel inventory may look like a clean demand signal, but supply constraints can obscure both lost sales and sustainable unit growth. The balance sheet reduces financing risk; it does not remove manufacturing or valuation risk. No price or valuation data are supplied, so avoid treating the buyback as proof shares are cheap.

Key Decisions for Investors

• Construct a small, staged long STAA position rather than chase the earnings reaction; add only after evidence that supply translates into unit growth, not just higher ASP. Upside case: improved availability and yield lift both volume and gross profit; downside: demand converts poorly and elevated unit costs persist.
• Use Q4 and the next operating update as checkpoints: require gross margin above Q3’s 70.9% and improving China unit shipments/backlog conversion before increasing exposure. A Q4 margin below 70.9%, or continued growth driven mainly by mix while units stall, would weaken the thesis.
• Keep presbyopia products out of the near-term earnings case. Track trial authorization and patient enrollment; delays or weak clinical progress would reduce long-dated optionality, not necessarily invalidate the core ICL business.
• No direct EL trade: the clinic-channel angle is speculative and does not establish a near-term earnings linkage.